NeuroSearch announces the end of stabilisation period in connection with the rights issue, completed November 2007

Announcement                                                                    


NeuroSearch announces the end of stabilisation period in connection with the
rights issue, completed November 2007 

With reference to announcement no. 29-07 from 27 November 2007, regarding the   
completion of a rights issue, NeuroSearch hereby announces that the             
stabilisation period expired on 28 December 2007. Carnegie Bank A/S and Danske  
Markets, division of Danske Bank A/S, acted as Joint Global Coordinators and    
stabilisation agents in connection with the rights issue.                       

The Joint Global Coordinators have notified the company that no stabilisation   
measures have been taken with regard to NeuroSearch A/S' shares within the      
stabilisation period.                                                           


Asger Aamund                                                                    
Chairman of the Board                                                           



--------------------------------------------------------------------------------
| Contact persons:                                   | Telephone:              |
|                                                    |                         |
--------------------------------------------------------------------------------
| Flemming Pedersen, CEO                             | +45 4460 8214 or        |
|                                                    | +45 2148 0118           |
--------------------------------------------------------------------------------
| Hanne Leth Hillman, Vice President,                | +45 4460 8212 or        |
| Director of Investor Relations & Corporate         | +45 4017 5103           |
| Communications                                     |                         |
--------------------------------------------------------------------------------




NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX
Nordic Exchange Copenhagen A/S. Our core business covers the development of     
novel drugs, based on a broad and well-established drug discovery platform      
focusing on ion channels and CNS disorders. A substantial part of the company's 
activities are partner financed through a broad alliance with GlaxoSmithKline   
(GSK) and collaborations with among others Abbott and Astellas. The drug        
pipeline comprises 13 clinical (Phase I-III) development programmes: ACR16 in   
Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase  
III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in     
partnership with GSK, NS1209 in epilepsy/pain (Phase II), ABT-894 in ADHD (Phase
II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia      
(Phase I) in partnership with Astellas, ACR325 in bipolar disorder/Parkinson's  
disease (Phase I), ABT-107 as well as ABT-560 for the treatment of various CNS  
diseases - both (Phase I) in collaboration with Abbott, NSD-644 in pain a.o.    
(Phase I) in partnership with GSK and ACR343 in Parkinson's disease (Phase I).  
In addition, NeuroSearch has a broad portfolio of preclinical drug candidates   
and holds equity interests in several biotech companies.